Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.43 |
| ▸ | F2 | P00734 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14582534 | 0.97 | F10 (0.43) | F10F2LMNAMAPK1KMT2A | |
| SCHEMBL14582532 | 0.96 | F10 (0.44) | F10F2LMNAMAPK1KMT2A | |
| SCHEMBL5472393 | 0.92 | F10 (0.42) | F10F2LMNAMAPK1KMT2A | |
| SCHEMBL5472527 | 0.92 | F10 (0.45) | F10F2LMNAMAPK1KMT2A | |
| SCHEMBL5475952 | 0.91 | F10 (0.45) | F10F2LMNAMAPK1KMT2A | |
| SCHEMBL14582530 | 0.89 | F10 (0.43) | F10F2LMNAMAPK1KMT2A | |
| SCHEMBL5470291 | 0.89 | F10 (0.44) | F10F2LMNAMAPK1KMT2A | |
| SCHEMBL5474672 | 0.89 | F10 (0.47) | F10F2LMNAMAPK1KMT2A | |
| SCHEMBL5475634 | 0.89 | F10 (0.42) | F10F2LMNAMAPK1KMT2A | |
| SCHEMBL14582531 | 0.87 | F10 (0.43) | F10F2LMNAMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032473-A1 | Substituted amides and their use as medicaments | GERLACH KAI | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032473-A1 | Substituted amides and their use as medicaments | OAT, HLA-B, BCAT2 | F10 1757/4885F2 461/4885LMNA 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.